PL3313373T3 - Stabilny ciekły preparat białka fuzyjnego z domeną igg fc - Google Patents

Stabilny ciekły preparat białka fuzyjnego z domeną igg fc

Info

Publication number
PL3313373T3
PL3313373T3 PL16814702.3T PL16814702T PL3313373T3 PL 3313373 T3 PL3313373 T3 PL 3313373T3 PL 16814702 T PL16814702 T PL 16814702T PL 3313373 T3 PL3313373 T3 PL 3313373T3
Authority
PL
Poland
Prior art keywords
igg
domain
fusion protein
liquid formulation
stable liquid
Prior art date
Application number
PL16814702.3T
Other languages
English (en)
Inventor
Soon Jae Park
Hye Shin Chung
Jun Young Kim
Original Assignee
Alteogen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57810344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3313373(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alteogen Inc. filed Critical Alteogen Inc.
Publication of PL3313373T3 publication Critical patent/PL3313373T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL16814702.3T 2015-06-23 2016-06-23 Stabilny ciekły preparat białka fuzyjnego z domeną igg fc PL3313373T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150089186 2015-06-23
KR1020160078234A KR101808234B1 (ko) 2015-06-23 2016-06-22 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
PCT/KR2016/006679 WO2016208989A1 (en) 2015-06-23 2016-06-23 A stable liquid formulation of fusion protein with igg fc domain

Publications (1)

Publication Number Publication Date
PL3313373T3 true PL3313373T3 (pl) 2025-03-03

Family

ID=57810344

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20195634.9T PL3824879T3 (pl) 2015-06-23 2016-06-23 Stabilny ciekły preparat białka fuzyjnego z domeną igg fc
PL16814702.3T PL3313373T3 (pl) 2015-06-23 2016-06-23 Stabilny ciekły preparat białka fuzyjnego z domeną igg fc

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL20195634.9T PL3824879T3 (pl) 2015-06-23 2016-06-23 Stabilny ciekły preparat białka fuzyjnego z domeną igg fc

Country Status (12)

Country Link
US (1) US9982032B2 (pl)
EP (3) EP3313373B1 (pl)
JP (1) JP6541875B2 (pl)
KR (3) KR101808234B1 (pl)
CN (2) CN107889457B (pl)
AU (1) AU2016283557B9 (pl)
CA (1) CA2990582C (pl)
ES (2) ES3007883T3 (pl)
MX (1) MX2017016907A (pl)
PL (2) PL3824879T3 (pl)
RU (1) RU2688679C1 (pl)
WO (1) WO2016208989A1 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
MX390837B (es) * 2015-10-16 2025-03-21 Regeneron Pharma Composiciones de proteinas estables.
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
CN109937034B (zh) * 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
KR101861163B1 (ko) * 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
WO2019020777A1 (en) * 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
US20200255496A1 (en) * 2017-09-18 2020-08-13 Amgen Inc. Vegfr-fc fusion protein formulations
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
WO2019099921A2 (en) * 2017-11-17 2019-05-23 Amgen Inc. Vegfr-fc fusion protein formulations
MY202872A (en) * 2017-11-20 2024-05-28 Just Evotec Biologics Inc Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
EP3730126B1 (en) * 2017-12-22 2025-05-14 Samsung Bioepis Co., Ltd. Liquid composition comprising vegf antagonist
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
WO2019173767A1 (en) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
GB201806918D0 (en) * 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
JP7855312B2 (ja) 2018-04-27 2026-05-08 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
WO2020055123A1 (ko) * 2018-09-10 2020-03-19 삼성바이오에피스 주식회사 단백질을 포함하는 액상 조성물
US20210353713A1 (en) 2018-10-26 2021-11-18 Amgen Inc. Formulations comprising a tris buffer and a protein
CN119033684A (zh) 2018-10-29 2024-11-29 豪夫迈·罗氏有限公司 抗体制剂
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
KR20210077645A (ko) * 2019-12-17 2021-06-25 주식회사 프로젠 신규 주사제 제형
EP3838260A1 (en) * 2019-12-20 2021-06-23 Ares Trading S.A. Igg:tgf rii fusion protein composition
WO2021123432A1 (en) * 2019-12-20 2021-06-24 Ares Trading S.A. Igg:tgfbetarii fusion protein composition
KR102337471B1 (ko) * 2019-12-23 2021-12-09 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질을 포함하는 약제학적 제형
EP4186492B1 (en) * 2020-07-24 2026-01-21 Pangen Biotech Inc. Ophthalmic liquid composition
EP4190310A4 (en) * 2020-07-31 2024-01-17 Celltrion, Inc. Stable pharmaceutical preparation
CN114324882B (zh) * 2020-10-12 2022-12-27 广东菲鹏生物有限公司 蛋白稳定剂及其应用
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
CN115518038A (zh) * 2021-06-25 2022-12-27 成都康弘药业集团股份有限公司 一种稳定的眼用制剂
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
AU2023331423A1 (en) * 2022-09-01 2025-02-13 Vegenics Pty Limited Pharmaceutical composition and method of using same
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2026142345A1 (ko) * 2024-12-24 2026-07-02 주식회사 알테오젠 Igg fc 도메인을 가지는 융합 단백질의 안정한 액상 제형

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA3142945A1 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン,エルエルシー タンパク質製剤
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
JP5419709B2 (ja) 2007-01-09 2014-02-19 ワイス・エルエルシー 抗il−13抗体製剤およびその使用
KR20130096731A (ko) * 2010-09-08 2013-08-30 할로자임, 아이엔씨 조건부 활성 치료적 단백질을 평가,확인 또는 진화시키는 방법
KR101698386B1 (ko) * 2010-10-06 2017-02-01 엘지디스플레이 주식회사 편광기능이 구비된 컬러필터층을 구비한 액정표시장치 및 이의 제조 방법
KR20180023015A (ko) * 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
EP2660251A1 (en) * 2012-04-30 2013-11-06 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Antibodies or fragments thereof against hemopexin for use in the treatment of ocular diseases
US20130323242A1 (en) * 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
WO2014078627A1 (en) * 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. Liquid formulations for tnfr:fc fusion proteins
SI4374873T1 (sl) 2013-07-12 2026-01-30 Astellas Us Llc Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj
CN105848645A (zh) * 2013-09-27 2016-08-10 韩美药品株式会社 持续型人生长激素制剂
ES2875878T3 (es) * 2013-11-18 2021-11-11 Formycon Ag Composición farmacéutica de un anticuerpo anti-VEGF
WO2015080513A1 (en) * 2013-11-29 2015-06-04 Hanwha Chemical Corporation A liquid formulation of a fusion protein comprising tnfr and fc region
CN105435222B (zh) 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂
JP6480154B2 (ja) 2014-11-06 2019-03-06 持田製薬株式会社 エタネルセプトの凍結乾燥製剤
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist

Also Published As

Publication number Publication date
ES3007559T3 (en) 2025-03-20
KR101808234B1 (ko) 2017-12-12
EP3313373A1 (en) 2018-05-02
JP2018517773A (ja) 2018-07-05
CN107889457A (zh) 2018-04-06
WO2016208989A1 (en) 2016-12-29
JP6541875B2 (ja) 2019-07-17
BR112017027945A2 (pt) 2018-08-28
EP4477233A2 (en) 2024-12-18
EP3313373B1 (en) 2024-11-27
ES3007883T3 (en) 2025-03-20
EP3824879A1 (en) 2021-05-26
MX2017016907A (es) 2018-04-18
AU2016283557A1 (en) 2017-12-14
RU2688679C1 (ru) 2019-05-22
US9982032B2 (en) 2018-05-29
CN114159386A (zh) 2022-03-11
CN107889457B (zh) 2021-11-12
EP4477233A3 (en) 2025-03-26
CA2990582C (en) 2020-06-09
KR20220130053A (ko) 2022-09-26
KR20170138387A (ko) 2017-12-15
KR20170000356A (ko) 2017-01-02
US20160376342A1 (en) 2016-12-29
EP3313373A4 (en) 2019-03-20
EP3313373C0 (en) 2024-11-27
EP3824879C0 (en) 2024-11-27
EP3824879B1 (en) 2024-11-27
PL3824879T3 (pl) 2025-03-10
CA2990582A1 (en) 2016-12-29
AU2016283557B2 (en) 2020-04-09
AU2016283557B9 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
PL3824879T3 (pl) Stabilny ciekły preparat białka fuzyjnego z domeną igg fc
IL278014A (en) Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
ZA201701810B (en) Sirp-alpha immunoglobulin fusion proteins
IL245754B (en) Liquid formulation of fusion protein containing tnfr and fc region
ZA201801669B (en) Liquid protein formulations containing ionic liquids
EP3241850A4 (en) Glp and immunoglobulin hybrid fc fused polypeptide and use thereof
SG11201706505PA (en) Stable liquid formulation for monoclonal antibodies
EP3261650A4 (en) Anti-dll3 chimeric antigen receptors and methods of use
IL247096A0 (en) proteins fc multimers
EP3188758C0 (en) SIRP ALPHA-ANTIBODY FUSION PROTEIN
EP3215523A4 (en) Anti-cldn chimeric antigen receptors and methods of use
EP3147298A4 (en) Pd-l1 fusion protein and use thereof
IL247246A0 (en) proteins fc multimers
IL246355B (en) p97–ids fused proteins
DK3199179T3 (da) Formulering af rekombinant fusionsprotein
PT3334747T (pt) Formulação de gonadotrofina líquida estável
EP3199555A4 (en) Recombinant fusion protein formulation
IL281003A (en) Dosing regimens of FC fusion protein with CD80 extracellular site
LT3464380T (lt) Gp100 specifinio tcr - anti-cd3 scfv sulieto baltymo dozavimo schema
SG11201606501PA (en) Nanobody-fluorescent protein fusion
EP3092248A4 (en) Fusion polypeptides and methods of use
SG11201710010WA (en) Applicator with liquid medicine
IL244857A0 (en) A fusion protein of acetylcholinesterase and the fc region
AU2016222891A1 (en) Anti-DLL3 chimeric antigen receptors and methods of use
TH1501006601A (th) สูตรทางเลือกสำหรับ TNFR:Fc ฟิวชันเพปไทด์